Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The type of hemodialysis access and preservation of this access greatly influences the quality of life and survival of patients undergoing hemodialysis. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for vascular access recommend the primary placement of native or autogenous hemodialysis fistulas in preference to polytetrafluoroethylene (PTFE) grafts and central venous catheters because the former form of access has fewer complications and a longer durability. However, autogenous hemodialysis fistulas, like polytetrafluoroethylene grafts, are also subject to dysfunction and eventual failure. Endovascular angioplasty has become an accepted alternative treatment to surgical revision for hemodialysis access-related venous stenoses and occlusions. However, the patency rates in the follow-up period are low because of the high frequency of restenosis due to intimal hyperplasia. Since 1988, noncovered stents have been used to improve fistula patency. In the central veins, bare stents demonstrate better patency rates than percutaneous transluminal angioplasty (PTA) alone. Neointimal hyperplasia is the major reason for restenosis following stent placement. The cephalic vein forms the outflow conduit for radiocephalic and brachiocephalic autogenous fistulas. It has recently been suggested that a focal area of the cephalic vein is prone to developing hemodynamically significant stenosis, in what is now termed the cephalic arch. This is the perpendicular portion of the cephalic vein in the region of the deltopectoral groove before its junction with the axillary vein. To overcome the problem of restenosis due to intimal hyperplasia in the cephalic arch the investigators used the insertion of a stent-graft as an alternative approach. In this study they investigated the use of a PTFE-covered nitinol stent-graft (Fluency, Bard) versus a Luminex (Bard) stent.


Options:
A: Arm Label: Conventional Balloon Angioplasty (COBA); Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: Drug Eluting Balloon Angioplasty (DEB); Type: EXPERIMENTAL; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Drug Eluting Balloon Angioplasty (DEB) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Conventional Balloon Angioplasty (COBA)
B: Intervention Type: DEVICE; Name: Stent or stent-graft deployment; Assigned to Arm(s): N/A
C: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: FLAIR; Type: EXPERIMENTAL; Interventions: Device: FLAIR Endovascular Stent Graft | Arm Label: PTA Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PTA | Arm Label: FLAIR Roll-in Participants; Type: EXPERIMENTAL; Interventions: Device: FLAIR Endovascular Stent Graft | Intervention Type: DEVICE; Name: FLAIR Endovascular Stent Graft; Assigned to Arm(s): FLAIR | Intervention Type: PROCEDURE; Name: PTA; Assigned to Arm(s): PTA Only | Intervention Type: DEVICE; Name: FLAIR Endovascular Stent Graft; Assigned to Arm(s): FLAIR Roll-in Participants

Answer: B